Mayne Pharma has more than doubled its full-year losses after the pharmaceutical company incurred a charge of $351.7 million due to the struggling US generic drug market.
from Breaking News | Daily Telegraph https://ift.tt/2Z5mVBk
from Breaking News | Daily Telegraph https://ift.tt/2Z5mVBk
Comments
Post a Comment